Comprehensive genomic evaluation of advanced and recurrent breast cancer patients for tailored precision treatments

Guidance on tailored precision therapy with consideration of genomic mutations was possible for some patients with information provided by F1CDx. Clinicians should consider using F1CDx at turning points in the course of the disease.